US FDA approves labeling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia (H Lundbeck A/S)

(Source: H Lundbeck A/S) Valby, Denmark, 2016-09-24 00:30 CEST (GLOBE NEWSWIRE) -- Labeling update includes clinical data on use of Rexulti in adult patients with schizophrenia in the maintenance phase of treatment Approval was based on Rexulti demonstrating efficacy and safety in a long-term randomized withdrawal trial The trial demonstrated a statistically significant, longer time to relapse in patients treated with Rexulti compared to placebo-treated patients Valby, Denmark and Princeton, New Jersey, 23 September 2016- H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) announced today that the US Food and Drug Administration (FDA) approved...